Marker Therapeutics, Inc. reports developments as a clinical-stage immuno-oncology company developing non-genetically modified Multi-Antigen Recognizing T cell therapies for hematologic malignancies and solid tumor indications. Its recurring company updates center on the MAR-T cell platform, MT-601 in lymphoma, MT-401-OTS as an off-the-shelf program, and pancreatic cancer research connected to technology developed at Baylor College of Medicine.
Company news also covers clinical observations from named studies, non-dilutive funding from government and cancer-research programs, scientific publications and medical-meeting presentations, quarterly financial results, conference participation, shareholder voting matters, and board governance changes.
Marker Therapeutics (NASDAQ:MRKR) has reported encouraging results from its Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing T cell product, for treating relapsed lymphoma. The study demonstrated a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with 50% achieving complete response.
The trial included 24 B-cell lymphoma patients across 7 U.S. clinical sites, with doses ranging from 100x106–400x106 cells. Notable outcomes include 78% objective response rate in Hodgkin Lymphoma patients and durable responses lasting 3-24 months. The treatment showed a favorable safety profile with no dose-limiting toxicities or serious adverse events.
The company is advancing to the dose expansion phase, investigating MT-601 at the maximum dose of 400x106 cells in DLBCL patients who have relapsed after or are ineligible for CAR-T therapy.
Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. CEO Dr. Juan Vera will engage in a fireside chat on August 12, 2025, from 12:30 to 12:55 p.m. EDT at the InterContinental Boston Hotel.
During the conference, management will conduct one-on-one meetings with investors to discuss their Multi-Antigen Recognizing (MAR) T cell platform and clinical developments. Investors can access the webcast through Marker's IR website under "Events and Presentations".
Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has announced its participation in Canaccord Genuity's Horizons in Oncology Virtual Conference. CEO Dr. Juan Vera will join a panel discussion titled 'CAR-T in Solid Tumors and New T-cell Approaches – Breakthroughs Ahead?' scheduled for April 7, 2025, from 11:00 AM to 11:50 AM ET.
The company specializes in developing next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors. Their innovative platform features multi antigen recognizing (MAR)-T cell therapy, designed to simultaneously target multiple tumor-associated antigens. This approach has demonstrated promising clinical results in both hematologic malignancies and solid tumors.
Marker Therapeutics (MRKR) reported its 2024 year-end results, highlighting significant progress in its lead program MT-601. The company's Phase 1 APOLLO study demonstrated promising results with a 78% objective response rate in lymphoma patients, including 44.4% complete responses. The therapy showed a favorable safety profile with minimal side effects.
MRKR secured $13 million in non-dilutive funding from CPRIT and NIH SBIR, and raised $16.1 million through a private placement. The company ended 2024 with $19.2 million in cash, expecting to fund operations into Q1 2026. Financial results showed R&D expenses of $13.5 million (up from $10.4M in 2023) and a net loss of $10.7 million (compared to $8.2M in 2023).
Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, announced that its President and CEO, Dr. Juan Vera, will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. This event will take place on February 25, 2025.
Dr. Vera is scheduled to present an overview of Marker’s technology and clinical developments on Tuesday, February 25, 2025, at 3:30 PM Eastern Time (ET). Registered participants can access the presentation through the event portal on the day of the event.
Marker Therapeutics (MRKR) has secured a $16.1 million private placement through the sale of 5,031,250 shares of common stock and accompanying warrants. The financing, priced at $3.20 per share, includes participation from Blue Owl Healthcare Opportunities, NEA, and Aisling Capital.
The proceeds will primarily support the clinical advancement of the company's Phase 1 APOLLO study investigating MT-601, a multi-antigen recognizing T cell product, in lymphoma patients who have relapsed after anti-CD19 CAR-T cell therapy or where such therapy isn't an option.
The warrants will be exercisable upon shareholder approval with a five-year term and an exercise price of $4.03 per share. Canaccord Genuity leads the placement with Brookline Capital Markets as co-placement agent.
Marker Therapeutics (MRKR) reported positive clinical updates from its Phase 1 APOLLO study of MT-601 in lymphoma patients. The study showed 78% objective response rates with 44.4% complete response in patients who relapsed after anti-CD19 CAR-T therapy or where CAR-T wasn't an option. Out of 10 treated patients, data is available for 9 participants from 5 U.S. clinical sites.
MT-601 demonstrated strong safety profile with no immune-effector cell associated neurotoxicity syndrome (ICANS) and only one Grade 1 cytokine release syndrome case. Long-term follow-up data of 6-12 months is available for three patients, with ongoing monitoring for response durability. The treatment showed efficacy in heavily pre-treated patients who had received 3-12 prior lines of therapy.